SCHEMBL2864855

SCHEMBL2864855

O=C(Oc1ccccc1)C1CNCC2C(=O)OC(c3cccc(F)c3)(c3cccc(F)c3)N12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
HCAR2 Q8TDS4 1/20 0.34
HSD11B1 P28845 1/20 0.34
FAAH O00519 1/20 0.34
TRPV1 Q8NER1 1/20 0.34
SLC6A9 P48067 2/20 0.33
USP2 O75604 2/20 0.33
CYP3A4 P08684 2/20 0.33
OPRM1 P35372 2/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP2C9 P11712 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GRIN2B Q13224 2/20 0.33
OPRK1 P41145 1/20 0.33
MC4R P32245 2/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
KCNH2 Q12809 1/20 0.33
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2856555 0.91 NPSR1 (0.38) KCNN4NPSR1ALDH1A1SMN1; SMN2
SCHEMBL6039789 0.89 NPSR1 (0.43) KCNN4NPSR1CYP3A4ALDH1A1CYP2C9
SCHEMBL2867203 0.89 NPSR1 (0.41) KCNN4NPSR1HSD11B1FAAHALDH1A1
SCHEMBL6039968 0.84 NPSR1 (0.35) NPSR1HSD11B1TRPV1HCRTR1HCRTR2
SCHEMBL2867869 0.80 L3MBTL1 (0.38) USP2ALDH1A1SMN1; SMN2
SCHEMBL2863274 0.78 ALDH1A1 (0.41) NPSR1USP2ALDH1A1
SCHEMBL2864543 0.78 POLB (0.38) KCNN4NPSR1TRPV1SMN1; SMN2MC4R
SCHEMBL6039954 0.78 NPSR1 (0.37) NPSR1CYP3A4ALDH1A1CYP2C9SMN1; SMN2
SCHEMBL2861757 0.78 NPSR1 (0.47) NPSR1ALDH1A1MC4R
SCHEMBL2856685 0.77 NPSR1 (0.49) KCNN4NPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 KCNN4 1295/4885NPSR1 211/4885HCAR2 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.